Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 13/20 | 0.98 |
| ▸ | ROCK1 known ✓ | Q13464 | 12/20 | 0.98 |
| ▸ | PRKCD known ✓ | Q05655 | 5/20 | 0.98 |
| ▸ | PRKD3 known ✓ | O94806 | 4/20 | 0.98 |
| ▸ | PRKCZ known ✓ | Q05513 | 4/20 | 0.98 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.98 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.98 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.98 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.98 |
| ▸ | PRKCG known ✓ | P05129 | 3/20 | 0.61 |
| ▸ | PRKCB known ✓ | P05771 | 3/20 | 0.61 |
| ▸ | PRKCA known ✓ | P17252 | 3/20 | 0.61 |
| ▸ | PRKCH known ✓ | P24723 | 3/20 | 0.61 |
| ▸ | PRKCI known ✓ | P41743 | 3/20 | 0.61 |
| ▸ | PRKCE known ✓ | Q02156 | 3/20 | 0.61 |
| ▸ | PRKCQ known ✓ | Q04759 | 3/20 | 0.61 |
| ▸ | PRKD1 known ✓ | Q15139 | 3/20 | 0.61 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL507871 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL29396389 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL29781011 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL2461354 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL2456059 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL507872 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL30009735 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL29372951 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL30069136 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL124161 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0885888-B1 | ISOQUINOLINE DERIVATIVES AND DRUGS | HIDAKA HIROYOSHI DR (JP) | 2003-08-13 | — | — | EP | claimed |
| US-6153608-A | Isoquinoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2000-11-28 | — | — | US | claimed |
| EP-0885888-A1 | ISOQUINOLINE DERIVATIVES AND DRUGS | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | claimed |
| JP-11349482-A | — | — | None | — | — | JP | disclosed |
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| EP-1295607-B9 | ANTITUMOR EFFECT POTENTIATORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| EP-1295607-B1 | ANTITUMOR EFFECT POTENTIATORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-04-28 | — | — | EP | disclosed |
| US-7696194-B2 | treating with fasudil hydrochloride; enzyme inhibitor of Rho kinase; promoting regeneration of an optic nerve cell | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20070088021-A1 | 4-haloisoquinoline derivative and drug containing the same | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2007-04-19 | — | — | US | disclosed |
| US-7109208-B2 | Visual function disorder improving agents | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| EP-0885888-B1 | ISOQUINOLINE DERIVATIVES AND DRUGS | HIDAKA HIROYOSHI DR (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-20030096843-A1 | Preventives/remedies for kidney diseases | MITSUBISHI PHARMA CORPORATION (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1295607-A1 | ANTITUMOR EFFECT POTENTIATORS | Mitsubishi Pharma Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1177796-A1 | PREVENTIVES/REMEDIES FOR LIVER DISEASES | Mitsubishi Pharma Corporation (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1174150-A1 | PREVENTIVES/REMEDIES FOR ANGIOSTENOSIS | Mitsubishi Pharma Corporation (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1163910-A1 | PREVENTIVES/REMEDIES FOR INTERSTITIAL PNEUMONIA AND PULMONARY FIBROSIS | Welfide Corporation (JP) | 2001-12-19 | — | — | EP | disclosed |
| US-6153608-A | Isoquinoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2000-11-28 | — | — | US | disclosed |
| JP-H11349482-A | MEDICAMENT | HIDAKA HIROYOSHI | 1999-12-21 | — | — | JP | disclosed |
| EP-0885888-A1 | ISOQUINOLINE DERIVATIVES AND DRUGS | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096843-A1 | Preventives/remedies for kidney diseases | RHOA, ROCK1, MMP1 | ROCK2 6/4885ROCK1 2/4885PRKCD 412/4885 |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | ROCK2 2882/4885ROCK1 2635/4885PRKCD 410/4885 |
| US-20070088021-A1 | 4-haloisoquinoline derivative and drug containing the same | ROCK1, CIT, ROCK2 | ROCK2 3/4885ROCK1 1/4885PRKCD 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.